Pfizer to present infectious disease data at IDWeek 2026

Pfizer Inc. is set to present a wealth of infectious disease data at the IDWeek 2026 congress, scheduled for October 21-24 in Washington, D.C. The company will showcase 12 oral presentations covering its infectious disease pipeline and portfolio, including data on pneumococcal disease, respiratory syncytial virus, Lyme disease, COVID-19, and meningococcal vaccines.

Key highlights include late-breaking Phase 2 data comparing Pfizer’s 25-valent pneumococcal conjugate vaccine candidate with PREVNAR 20 in healthy infants, and Phase 3 results from the VALOR study on a 6-valent Lyme disease vaccine candidate. Additionally, Pfizer will present real-world data on its RSV vaccine, ABRYSVO, and effectiveness data for PREVNAR 20 against invasive pneumococcal disease in U.S. adults 65 years and older.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.